Laboratory of Anesthesia and Critical Care Medicine, Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Eur Rev Med Pharmacol Sci. 2023 Feb;27(4):1322-1335. doi: 10.26355/eurrev_202302_31366.
Myoclonus is one of the main complications of etomidate anesthesia, which would develop into serious consequences during surgery. The present analysis was performed to evaluate systematically the effect of propofol on preventing etomidate-induced myoclonus in adult patients.
Systematic electronic literature search was performed in the databases PubMed, Cochrane Library, OVID, Wanfang and China National Knowledge Infrastructure (CNKI) from inception to May 20, 2021, without any language restrictions. All randomized controlled trials evaluating the efficacy of propofol on preventing etomidate-induced myoclonus were enrolled. The primary outcome included the incidence and degree of etomidate-induced myoclonus.
1,420 patients (with 602 received etomidate anesthesia and 818 received propofol plus etomidate anesthesia) from 13 studies were eventually included. Whatever the intravenous propofol dose for anesthesia induction 0.8-2 mg/kg (RR:4.04, 95% CI [2.42,6.74] p<0.0001, I2=56.5%), or the dose of propofol for anesthesia induction 0.5-0.8 mg/kg (RR:3.26, 95% CI [2.03,5.22] p<0.0001, I2=0%), or the dose of propofol for anesthesia induction 0.25-0.5mg/kg (RR:1.68, 95% CI [1.1,2.56] p=0.0160, I2=0%), combination of propofol and etomidate could significantly decrease the occurrence of etomidate-related myoclonus (RR=2.99, 95% CI [2.40, 3.71] p<0.0001, I2=43.4%), compared with etomidate alone. In addition, propofol plus etomidate attenuated the incidence of mild (RR:3.40, 95% CI [1.7,6.82] p=0.0010, I2=54.3%), moderate (RR:5.4, 95% CI [3.01, 9.67] p<0.0001, I2=12.6%), severe (RR:4.15, 95% CI [2.11, 8.13] p<0.0001, I2=0%) of etomidate-induced myoclonus without adverse effects except for the increased incidence of pain on injection (RR:0.47, 95% CI [0.26, 0.83] p=0.0100, I2=41.5%) compared with etomidate alone.
The meta-analysis currently generates the evidence of combination of propofol with the dosage of 0.25-2 mg/kg and etomidate can alleviate the occurrence and severity of etomidate-induced myoclonus, with decreased incidence of postoperative nausea and vomiting (PONV) and comparative side effects of hemodynamic and respiratory depression of patients in comparison with etomidate alone.
肌阵挛是依托咪酯麻醉的主要并发症之一,在手术过程中会发展成严重的后果。本分析旨在系统评估丙泊酚预防成人患者依托咪酯诱导肌阵挛的效果。
从建库到 2021 年 5 月 20 日,在 PubMed、Cochrane Library、OVID、万方和中国知网(CNKI)数据库中进行了系统性电子文献检索,无任何语言限制。所有评估丙泊酚预防依托咪酯诱导肌阵挛效果的随机对照试验均被纳入。主要结局包括依托咪酯诱导肌阵挛的发生率和严重程度。
最终纳入 13 项研究的 1420 名患者(602 名接受依托咪酯麻醉,818 名接受丙泊酚加依托咪酯麻醉)。无论静脉注射丙泊酚诱导麻醉的剂量为 0.8-2mg/kg(RR:4.04,95%CI[2.42,6.74],p<0.0001,I2=56.5%),还是丙泊酚诱导麻醉的剂量为 0.5-0.8mg/kg(RR:3.26,95%CI[2.03,5.22],p<0.0001,I2=0%),或丙泊酚诱导麻醉的剂量为 0.25-0.5mg/kg(RR:1.68,95%CI[1.1,2.56],p=0.0160,I2=0%),丙泊酚和依托咪酯联合应用均可显著降低依托咪酯相关肌阵挛的发生(RR:2.99,95%CI[2.40,3.71],p<0.0001,I2=43.4%),与依托咪酯单独使用相比。此外,丙泊酚加依托咪酯还可减轻轻度(RR:3.40,95%CI[1.7,6.82],p=0.0010,I2=54.3%)、中度(RR:5.4,95%CI[3.01,9.67],p<0.0001,I2=12.6%)、重度(RR:4.15,95%CI[2.11,8.13],p<0.0001,I2=0%)依托咪酯诱导肌阵挛的发生率,且无不良事件发生,除注射痛的发生率增加(RR:0.47,95%CI[0.26,0.83],p=0.0100,I2=41.5%)外,与依托咪酯单独使用相比。
目前的荟萃分析结果表明,丙泊酚与 0.25-2mg/kg 剂量联合使用可减轻依托咪酯诱导的肌阵挛的发生和严重程度,与依托咪酯单独使用相比,降低了术后恶心呕吐(PONV)的发生率,并减少了患者的血流动力学和呼吸抑制等不良反应。